SteinCares
SteinCares is a Costa Rica-based specialty healthcare company that licenses, registers, and distributes biosimilars and complex generics across 30 Latin American countries through exclusive partnerships with global biopharmaceutical developers.
- Company typePrivate
- Founded1980
- HeadquartersSan José, Costa Rica
- Headcount251–500
- GTM typeB2B
- OfferingServices
SteinCares firmographics
Firmographics- Name
- SteinCares
- Legal name
- SteinCares S.A.
- Website
- https://steincares.com
- Company type
- Private
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- SteinCares is a Costa Rica-based specialty healthcare company that licenses, registers, and distributes biosimilars and complex generics across 30 Latin American countries through exclusive partnerships with global biopharmaceutical developers.
- Ownership category
- akta.pro rank
SteinCares industry classification
Industry- Product category
- Specialty Pharmaceuticals
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Hospital Shared Services, GPOs & System Support Organizations (HLAFAAAO)
Keywords
Where SteinCares is headquartered
LocationHeadquarters
- HQ city
- San José
- HQ country
- Costa Rica
- HQ region
- Latin America
Offices1 record
Markets served
SteinCares business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Marketing or Sales, Supply Chain, Others
Revenue model
- Biosimilar Licensing and Distribution: SteinCares generates revenue through exclusive licensing agreements to register, commercialize, and distribute biosimilar products across Latin American markets. The company partners with development and manufacturing firms to bring cost-effective treatments to the region.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
SteinCares product offering
Product offeringCore offering
SteinCares is a Costa Rica-based specialty healthcare company that acquires exclusive rights to register, commercialize, and distribute biosimilars, complex generics, and innovative pharmaceuticals across 30 countries in Latin America. The company leverages strategic licensing agreements with international biopharmaceutical developers (e.g., Shilpa Biologicals, Bio-Thera Solutions) and combines regional regulatory expertise with commercialization and distribution infrastructure to expand patient access to cost-effective specialty medicines.
Product overview
SteinCares operates as a specialty healthcare company offering a unified platform for biosimilar medicines across Latin America. The company provides integrated services combining regional regulatory expertise, commercialization capabilities, and distribution infrastructure spanning 30 countries. SteinCares leverages partnerships with biopharmaceutical developers (such as Shilpa Biologicals and Bio-Thera Solutions) to register, commercialize, and distribute biosimilar products, focusing on expanding patient access to cost-effective treatments for chronic inflammatory and other diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Biosimilar Commercialization Platform An integrated platform spanning 30 Latin American countries that handles regulatory registration, commercialization, and distribution of biosimilar medicines on behalf of development partners; serves healthcare systems, payers, and patients across the region seeking affordable specialty treatments.
- Dupilumab Biosimilar (IL-4 Antibody) A proposed biosimilar of dupilumab targeting IL-4 antibody-based treatments for chronic inflammatory diseases; SteinCares holds exclusive rights to register, commercialize, and distribute across Latin America; serves patients with chronic inflammatory conditions and healthcare systems/payers seeking affordable specialty treatments.
- Shilpa Biologicals Biosimilar (Latin America Rights) A biosimilar developed and manufactured by Shilpa Biologicals in India, with SteinCares holding exclusive rights to register, commercialize, and distribute across 30 Latin American countries; serves healthcare systems, payers, and patients across the region.
Quantifiable outcome
- Improved access to specialty medicines across Latin America
- +1 more outcomes
Companies that use SteinCares
Customer profileSegments2 records
Ideal customer profiles2 records
SteinCares technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
SteinCares partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Shilpa BiologicalscoreStrategic licensing agreement where SteinCares holds exclusive rights to register, commercialize, and distribute a biosimilar across Latin America while Shilpa Biologicals handles product development and manufacturing at its facility in Dharwad, India. The partnership marks Shilpa Biologicals' entry into the Latin American market and combines their biologics development expertise with SteinCares' integrated regional platform spanning 30 countries.
- Bio-Thera Solutions Ltd.corePartnership to commercialize a proposed biosimilar of dupilumab for treating chronic inflammatory diseases throughout Latin America. The alliance combines Bio-Thera Solutions' biologics development expertise with SteinCares' regional registration and commercialization capabilities to expand access to IL-4 antibody-based treatments in emerging markets.
Scale indicators3 records
Recent moves4 records
Expansion highlights5 records
SteinCares competitors and assessment
Company assessmentDirect peers
- Eurofarma: Brazilian-founded multinational pharmaceutical company with deep Latin American presence across generics, branded generics, and biosimilars. Eurofarma is comparable to SteinCares as a major regional specialty/generics platform operating across multiple LATAM markets and pursuing biosimilar partnerships.
- Adium: Latin American specialty pharmaceutical company focused on oncology, specialty care, and rare diseases, with presence in more than 20 countries. Adium is comparable to SteinCares as a regional specialty pharma commercialization platform that licenses and distributes advanced therapies across LATAM.
- Hikma Pharmaceuticals: Multinational pharmaceutical company headquartered in Jordan/UK with significant presence in MENA, North America, and emerging markets, focused on generics and specialty medicines. Hikma is comparable to SteinCares as a generic/specialty pharma operator with a multi-country emerging-market distribution footprint.
- Laboratorios Pisa: Mexican pharmaceutical company with regional presence focused on generics, biosimilars, and specialty medicines. Laboratorios Pisa is comparable to SteinCares as a LATAM specialty/generics platform serving healthcare systems with cost-effective pharmaceutical products.
Broad incumbents
- Teva Pharmaceutical Industries: Israel-based multinational and the world's largest generic drug manufacturer, with a sizable biosimilar portfolio and global commercial reach. Teva is comparable to SteinCares as a global generic/biosimilar leader whose breadth and capital pose a competitive threat to regional intermediaries.
- Sandoz: Global leader in generics and biosimilars, spun out of Novartis as a standalone company in 2023, with worldwide commercialization capabilities. Sandoz is comparable to SteinCares as a major biosimilar player whose direct LATAM entry could bypass regional licensing partners.
- Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical company with global manufacturing and distribution operations, including a growing biosimilar pipeline. Amneal is comparable to SteinCares as a broad generic/specialty pharma player with emerging-market distribution ambitions.
Emerging players
- Biocon: Indian biopharmaceutical company with a global biosimilar portfolio (insulin, trastuzumab, bevacizumab, etc.) and commercial partnerships in emerging markets. Biocon is comparable to SteinCares as a biosimilar developer that competes with — and often partners with — regional LATAM distributors.
- Samsung Bioepis: South Korean biosimilar developer (Samsung Biologics/Biogen joint venture) commercializing biosimilars globally through licensing and direct partnerships. Samsung Bioepis is comparable to SteinCares as a biosimilar counterpart that may license to or bypass regional LATAM distributors.
- Celltrion: South Korean biopharmaceutical company and one of the world's largest biosimilar manufacturers, with a global commercialization strategy. Celltrion is comparable to SteinCares as a major biosimilar supplier whose LATAM route-to-market choices affect regional distributor economics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
SteinCares social profiles
Digital presenceSteinCares financial estimates
Financial estimateRevenue estimate
Valuation estimate
SteinCares leadership team
Management profileNumber of profiles
Profiles1 record
SteinCares funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SteinCares M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SteinCares
What does SteinCares do?
SteinCares is a Costa Rica-based specialty healthcare company that acquires exclusive rights to register, commercialize, and distribute biosimilars, complex generics, and innovative pharmaceuticals across 30 countries in Latin America. The company leverages strategic licensing agreements with international biopharmaceutical developers (e.g., Shilpa Biologicals, Bio-Thera Solutions) and combines regional regulatory expertise with commercialization and distribution infrastructure to expand patient access to cost-effective specialty medicines.
Is SteinCares a public or private company?
SteinCares is a private company. It is classified as private equity controlled and is currently operating.
When was SteinCares founded?
SteinCares was founded in 1980. It employs 251 to 500 people.
Where is SteinCares based?
SteinCares is headquartered in San José, Costa Rica, in the Latin America region.
How does SteinCares make money?
One revenue line is on record: biosimilar Licensing and Distribution.
Who are SteinCares's main competitors?
Direct peers on record are Eurofarma, Adium, Hikma Pharmaceuticals and Laboratorios Pisa. Broad incumbents are Teva Pharmaceutical Industries, Sandoz and Amneal Pharmaceuticals. Emerging players are Biocon, Samsung Bioepis and Celltrion.
Does SteinCares have an API?
No public API is recorded for SteinCares.
What industry is SteinCares in?
SteinCares's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAFAAAO, Hospital Shared Services, GPOs & System Support Organizations. Its SIC code is 5122.